Medpace Holdings (MEDP) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $4.84
- Estimate
- $4.46
- Surprise
- +8.5%
- Score today
- 6.3/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
How the report landed
Medpace Holdings (MEDP) beat the $4.46 estimate with adjusted EPS of $4.84 — a clear 8.5% upside surprise.
Where TrendMatrix's rating stands now
TrendMatrix currently rates MEDP Buy (Wait) at 6.3/10; no pre/post engine snapshot brackets this report.
4 of the last 4 quarters beat the estimate; this quarter's +8.5% surprise compares with a +8.3% four-quarter average.
What supports the rating
- V7 quality resilience bonus: +0.2 (Q=8.0 in RISK_OFF)
- Sector modifier (Healthcare): +0.5
What argues against it
- Concentration risk — Customer: small biopharmaceutical companies (82.0%)
- Analyst target reached - limited upside remaining
- Near 52-week high (2.3% away)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $662.48
- Entry target
- $629.36
- Stop
- $585.30
At 36.8× trailing and 34.3× forward earnings, consensus estimates imply little change in earnings power.
Risk check: RSI 72 — a level conventionally read as overbought; gains at these levels often lean on momentum; trading volume is running 3.4× its average — elevated turnover around the report window.
Model outputs from TrendMatrix’s engine as of 2026-10-22 — shown for context, not personalized investment advice.
MEDP at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Diagnostics & Research
- Market cap
- $18.49B
- P/E (fwd)
- 34.3
- P/E (ttm)
- 36.8
- 52-week range
- $373.00–$677.90
- Off 52-week high
- 2.3%
- RSI (14)
- 72
- Volume vs avg
- 3.39×
- Score today
- 6.3/10